T-Therapeutics raises $133M with Lilly aboard to take T cell engagers into the clinic
Advent Life Sciences and the British Business Bank co-led the oversubscribed Series B for the Cambridge, U.K., company, which has now announced $224 million across two rounds.

- Amount
- $133M
- Type
- Series B
- Company
- T-Therapeutics
- Led by
- Advent Life Sciences, British Business Bank
- Sector
- Biotech
- Announced
- Nov. 5, 2026
T-Therapeutics has yet to test a drug in people. A year after expanding its Series A, the Cambridge, U.K., company has raised $133 million to change that, with Eli Lilly and Co. among the new names on its shareholder list.
The company said Nov. 5 that it closed an oversubscribed Series B to take its two lead programs, one in cancer and one in autoimmune disease, into clinical trials and through clinical proof of concept. The company describes both as TCR-CD3 bispecific T cell engagers.
Why it matters: The round more than doubles the money T-Therapeutics has announced, to $224 million across two rounds, and it adds Lilly as a shareholder as the company moves from research to clinical development. Its pitch is a platform that it says can reach intracellular targets long considered undruggable.
New investors Advent Life Sciences and the British Business Bank co-led the round. Other new investors were JJDC, Samsara BioCapital, M-Ventures and Lilly. All of the company's existing major shareholders also took part: Sofinnova Partners, F-Prime, Digitalis Ventures, Cambridge Innovation Capital, Sanofi Ventures, Tencent and BGF. T-Therapeutics did not disclose a valuation.
Representatives of Advent, the British Business Bank, JJDC and Samsara will join the board as non-executive directors.
The platform and the programs
T-Therapeutics said both programs come from its OpTiMus platform, which it says supplies fully human T cell receptors and opens up validated intracellular targets that were previously out of reach. In its November 2025 announcement, the company said its lead cancer drug goes after what it called a pan-tumour driver target found across multiple solid tumor types, and that its lead immunology program aims to reset the immune system by selectively depleting the immune cells that drive disease. Neither announcement named the targets.
Dominic Schmidt, a general partner at Advent Life Sciences, said in the release that T cell engagers have had clinical success in blood cancers but have struggled in solid tumors because suitable targets are scarce, a gap he said the company's platform is designed to fill.
"This financing is a key step in our transition to a clinical-stage company," Theodora Harold, T-Therapeutics' chief executive, said.
The company also hired Kirsty Crame as chief development officer to run translational and clinical development. Crame was previously chief medical officer at Curatis AG and led early-stage clinical programs at Medigene AG and Gadeta BV, according to the announcement.
How the money adds up
The Series B follows a Series A that T-Therapeutics expanded in November 2025, when it raised a further $32 million on top of an initial $59 million for a $91 million total. Tencent and BGF joined as new investors at that time. The two rounds the company has announced total $224 million.
What to watch
T-Therapeutics did not say when either program will enter the clinic, which diseases its first trials will target or what the targets are. Those are the next disclosures to watch, along with the timing of the clinical proof-of-concept data the round is meant to fund.



